Tandem Diabetes Care (TNDM) shares have seen swings lately, with investors keeping a close eye on the company’s longer-term performance and valuation after a challenging year for its stock price and financials.

Tandem Diabetes Care’s share price has bounced sharply in the past month with a 12.8% gain, though that momentum has not reversed a tough broader stretch, as the total shareholder return over the last year remains down more than 56%. Investors appear to be weighing signs of operational progress against lingering uncertainty, meaning sentiment could shift quickly from here.

If you’re keeping an eye on healthcare stocks showing resilience or ready for a rebound, it’s worth discovering See the full list for free.

With the stock trading at a significant discount to analyst targets and some signs of improving fundamentals, the key question is whether Tandem Diabetes Care is now undervalued or if the market already reflects its growth prospects.

Most Popular Narrative: 33.5% Undervalued

The consensus narrative points to a fair value far above Tandem Diabetes Care’s latest close, suggesting the market may be missing the story. Skepticism remains, but the outlined path to growth relies on a combination of channel expansion, new product launches, and policy shifts.

Broader pharmacy channel expansion and acceleration of pharmacy-based supply sales are expected to lower out-of-pocket costs, increase pump adoption rates, and shift more high-margin recurring supply sales through premium-priced channels. This supports future revenue growth, margin expansion, and improved earnings.

Just how bold are these future revenue and margin assumptions? The story hinges on a powerful combination of recurring sales and diabetic tech innovation, along with some ambitious profit expectations. Want to find out the crucial financial lever that could make or break this valuation? The key number that sets up this high bar might surprise even experienced investors.

Result: Fair Value of $21.05 (UNDERVALUED)

However, risks remain, including heightened U.S. competition and execution uncertainty. Either of these factors could quickly shift Tandem Diabetes Care’s current recovery story.

Build Your Own Tandem Diabetes Care Narrative

If you want to dig deeper, the data is yours to explore and it only takes a few minutes to build a narrative that fits your own take. Do it your way

A good starting point is our analysis highlighting 3 key rewards investors are optimistic about regarding Tandem Diabetes Care.

Looking for more investment ideas?

Smart investors always have options, and the right screener can lead you to your next winning stock. Don’t let a great opportunity slip away while you’re focused on just one company.

• Boost your income potential and uncover top performers by reviewing these 22 dividend stocks with yields > 3% with high yields and robust growth.
• Capitalize on the AI wave and tap into tomorrow’s leaders by scanning these 26 AI penny stocks making breakthroughs across industries.
• Spot overlooked market gems and seize opportunities others are missing by searching these 831 undervalued stocks based on cash flows for stocks trading below their real worth.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.